IQV - IQVIA Holdings Inc.

NYSE - NYSE Delayed Price. Currency in USD
154.82
-1.90 (-1.21%)
At close: 4:02PM EDT

154.82 0.00 (0.00%)
After hours: 5:04PM EDT

Stock chart is not supported by your current browser
Previous Close 156.72
Open 156.92
Bid 155.13 x 900
Ask 155.16 x 1100
Day's Range 154.77 - 157.11
52 Week Range 104.90 - 164.13
Volume 543,124
Avg. Volume 1,256,468
Market Cap 30.328B
Beta (3Y Monthly) 1.11
PE Ratio (TTM) 127.95
EPS (TTM) 1.21
Earnings Date Oct 21, 2019 - Oct 25, 2019
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 176.12
Trade prices are not sourced from all markets
  • Business Wire

    IQVIA Launches Patient Portal to Transform the Clinical Trial Experience

    IQVIA™ (IQV) announces its launch of the IQVIA Patient Portal, a global web-based solution built on a leading health cloud platform. This innovative tool enables increases in clinical trial patient recruitment, engagement and retention by ensuring transparency and collaboration before, during, and after a clinical study. Trial participants are invited to join the IQVIA Patient Portal when they are recruited.

  • 3 Top Biotech Stocks to Buy in August
    Motley Fool

    3 Top Biotech Stocks to Buy in August

    In the high-risk world of biotech investing, there are no guarantees of success. Still, sometimes investors can find places where the odds look reasonable enough to consider buying shares.

  • IQVIA Holdings (NYSE:IQV) Has A Pretty Healthy Balance Sheet
    Simply Wall St.

    IQVIA Holdings (NYSE:IQV) Has A Pretty Healthy Balance Sheet

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • Business Wire

    IQVIA Announces Repurchase of Common Stock

    IQVIA Holdings Inc. today announced that it has agreed to purchase an aggregate of 1,000,000 shares of its common stock in a private transaction from certain of its existing stockholders .

  • 3 Keys to Investing in Next-Gen Healthcare Stocks
    InvestorPlace

    3 Keys to Investing in Next-Gen Healthcare Stocks

    Picture a bizarre clothing store for a moment …Source: Shutterstock You walk in. An employee sizes you up and asks you if there's anything in particular you're looking for. After learning that you're a size "large" and that you'd like some new dress shirts, the employee takes you to a table covered with them. All of the shirts are the same size. All XL, extra-large."Strange," you think, and go to another table covered with shirts. All the shirts are the same size. All XL.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"Stranger," you think, and go to another table covered with shirts. Once again, all the shirts are the same size. All XL.Sensing your confusion, the employee explains the store's "one size fits all" policy. The owners know people come in many shapes and sizes, but XL is the only size of clothes they can get from their suppliers.You walk out of the "one size fits all" store, thinking it's one of the most ridiculous things you've ever seen.A "one size fits all" clothing store isn't much different than America's healthcare system.Lacking the resources to treat us as individuals -- with different genetic makeups, different diets, and living in different environments -- doctors frequently resort to treating patients with "one size fits all" procedures and medicines. And since most doctors rush patients in and out of the office to boost profits, the pressure to use sub-par, "one size fits all" treatments is massive.Don't get me wrong: Our approach to health and medicine is light years ahead of where it was in the 1800s. Bloodletting is no longer a "go to" move for doctors.However, many of the decisions made by today's healthcare professionals will look medieval when compared to the treatments of the near future. They simply don't take into account that every case is different -- that we are all unique. Take the drug commercials you see on television … which go on to list lots of horrible side effects of popular drugs (which don't work for everyone who takes them).Soon, we'll say goodbye to those types of treatments. That's because the age of customized, "precision" healthcare is getting started. The result will be a massively improved healthcare system … and some of the biggest wealth building opportunities of your life.In today's essay, I'll describe the three key innovations that will take us into the age of precision medicine. Investors will want to pay attention. In America, we spend $3.5 trillion -- about 18% of GDP -- on healthcare. When something big happens in healthcare, it creates giant ripple effects in the economy that enrich those who know what's happening. Trillion-Dollar Innovation 1: Genome SequencingEvery cell in your body has a set of genetic instructions that dictate what you look like, what your athletic abilities are, what your mental abilities are, what diseases you're likely to get, and dozens of other key things that make you YOU.This set of instructions is called your genome. Determining exactly what your genome says is a process called genome sequencing.In 2003, an international research organization called The Human Genome Project sequenced a human genome for the first time. The project's price tag was an enormous $3 billion.Thanks to incredible advances in computing power, that same sequencing can be performed today for less than $1,000. And in a few years the price will be as low as a dinner for two.Genome sequencing is a critical part of precision medicine because it allows medical professionals to get an incredibly detailed analysis of who you are. As a result of this information, doctors can recommend treatments that are right for you.Sixteen years ago, getting this kind of detailed information was prohibitively expensive. But now that costs are down more than 99% and poised to go down even more, genome sequencing is about to go mainstream.Genetic testing will become part of regular medical care … just like taking your pulse and your blood pressure. It's going to usher in an era of much more effective healthcare. In large part to innovation 2 … Trillion-Dollar Innovation 2: Digital Patient RecordsIt's one thing to have lots of information. It's an entirely different -- and more valuable -- thing to be able to analyze that information and use it to make quality decisions.This is where digital patient records come in.Genome sequencing will produce vast amounts of information that will need to be stored and analyzed. Just as the processing power of our computers has increased by leaps and bounds since 2003, our ability to collect and store information has increased as well. This continued growth is a key part of precision medicine. That's because genome sequencing is going to generate a stupendous amount of information.It is predicted that the amount of storage capacity for all human genome data will increase to 40 exabytes by 2025. To put that into perspective, experts believe all videos on YouTube will require 1-2 exabytes of storage and Twitter will require .001 to .017 exabytes.As for analyzing all that data, we come to Innovation 3 … Trillion-Dollar Innovation 3: AI DoctorsAs you can guess, we're not going to sift through some of the world's largest data sets with a pen and paper in hand.We're going to use artificial intelligence (AI) to perform advanced data analysis. AI programs will sift through data to identify treatments that work for patients with specific genetic conditions.These programs will be able to do more "thinking" in one minute than millions of doctors could do in a decade. It's going to revolutionize healthcare.In fact, I believe that within the next 30 years, AI will know how various combinations of molecules will affect patients on the individual level. We'll have giant databases of patients and their genetic makeups … and we'll be able to test new drugs with computer simulations. The time it takes to devise, test, and produce new life-saving drugs will be massively condensed. Plus, the cost of doing it all will plummet.We'll have vast databases of human genomes and the ability to create and test new customized treatments in seconds. It could easily become the most valuable technology on the planet. Again, this is many years away, but I believe it's going to happen. Summing UpOne size fits allThanks to the technological limitations of the past, our healthcare system is based on treatments that are not tailored to your genetic makeup. We're using "shotgun" approaches instead of targeted approaches.However, thanks to cheap and widespread genome sequencing, digital record keeping, and artificial intelligence, we're about to enter an amazing era of precision, personalized medicine.Over the next 20 years, the healthcare system we know and don't love will change dramatically. We'll look back at some of today's treatments as medieval.Remember: In America, we spend $3.5 trillion -- about 18% of GDP -- on healthcare. When something big happens in the industry, it creates giant ripple effects. That's why the precision medicine revolution is one of the greatest wealth building opportunities of your life.The opportunities are not in the old school big pharma names like Johnson & Johnson. They are in precision medicine and the technologies that will enable it.Everything from digital records company Cerner (NASDAQ:Cern) to gene testing pioneer Illumina (NASDAQ:ILMN) to contract research services firm IQVIA Holdings (NYSE:IQV) will take the lead in the future of precision medicine.And keep an eye on the IPO market here as well. We'll see waves of early stage companies going public … many with the potential to not only revolutionize medicine, but revolutionize your net worth as well.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 9 Retail Stocks Goldman Sachs Says Are Ready to Rip * 7 Services Stocks to Buy for the Rest of 2019 * 6 Stocks to Buy and 1 to Sell Based on Insider Trading The post 3 Keys to Investing in Next-Gen Healthcare Stocks appeared first on InvestorPlace.

  • Business Wire

    IQVIA Named Real World Evidence Leader

    Biopharma companies pick IQVIA as the leader in real world data and evidence services in new Life Science Strategy Group report

  • Business Wire

    IQVIA’s Cynthia Verst Honored on 2019 PharmaVOICE 100 List

    IQVIA™ today announced that Cynthia Verst, IQVIA’s president, Design and Delivery Innovation, Research & Development Solutions, has been named to PharmaVOICE magazine’s annual list of the 100 most influential and inspiring individuals within the life sciences industry.

  • 10 Bargain Blue Chips Seen Surging As Fed Lowers Rates
    Investopedia

    10 Bargain Blue Chips Seen Surging As Fed Lowers Rates

    Low-valuation, high-leveraged stocks have led the market in recent months and are poised to outperform.

  • Business Wire

    IQVIA Announces Pricing of Offering of Senior Notes

    IQVIA Holdings Inc. (“IQVIA”) (IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an offering of €720,000,000 in aggregate principal amount of senior notes due 2028 (the “Notes”). The Notes to be offered have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act.

  • Moody's

    IQVIA Inc. -- Moody's assigns Ba3 rating to IQVIA's new senior unsecured notes

    Moody's Investors Service ("Moody's") assigned a Ba3 rating to the proposed senior unsecured notes of IQVIA Inc. ("IQVIA"). There are no changes to IQVIA's existing ratings, including the Ba2 Corporate Family Rating, Ba2-PD Probability of Default Rating, and SGL-1 Speculative Grade Liquidity Rating. IQVIA will use proceeds from the notes offering to refinance existing unsecured notes.

  • Business Wire

    IQVIA Announces Offering of Senior Notes

    IQVIA Holdings Inc. (“IQVIA”) (IQV) today announced that its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $800,000,000 equivalent in gross proceeds through an offering of euro-denominated senior notes due 2028. IQVIA also announced that the Issuer delivered a conditional notice of redemption with respect to its outstanding 4.875% senior notes due 2023 (the “4.875% Notes”). Certain statements in this press release are forward-looking statements.

  • Thomson Reuters StreetEvents

    Edited Transcript of IQV.N earnings conference call or presentation 24-Jul-19 1:00pm GMT

    Q2 2019 IQVIA Holdings Inc Earnings Call

  • IQVIA Holdings Boosts Guidance After a Strong Quarter
    Motley Fool

    IQVIA Holdings Boosts Guidance After a Strong Quarter

    Everything is going well for the life sciences service provider.

  • IQVIA Holdings Inc. (IQV) Q2 2019 Earnings Call Transcript
    Motley Fool

    IQVIA Holdings Inc. (IQV) Q2 2019 Earnings Call Transcript

    IQV earnings call for the period ending June 30, 2019.

  • IQVIA Holdings (IQV) Beats on Q2 Earnings, Updates '19 View
    Zacks

    IQVIA Holdings (IQV) Beats on Q2 Earnings, Updates '19 View

    IQVIA Holdings (IQV) second-quarter 2019 earnings and revenues improve on a year-over-year basis.

  • IQVIA Holdings (IQV) Surpasses Q2 Earnings and Revenue Estimates
    Zacks

    IQVIA Holdings (IQV) Surpasses Q2 Earnings and Revenue Estimates

    IQVIA (IQV) delivered earnings and revenue surprises of 2.68% and 1.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • ACCESSWIRE

    IQVIA Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 24, 2019 / IQVIA Holdings, Inc. (NYSE: IQV ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 24, 2019 at 9:00 AM Eastern ...

  • Business Wire

    IQVIA Reports Second-Quarter 2019 Results, Raises Full-Year Revenue and Adjusted Diluted EPS Guidance

    DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.-- -- Second-quarter revenue $2,740 million Adjusted EBITDA $578 million GAAP Diluted Earnings per Share $0.30; Adjusted Diluted Earnings per Share $1.53 $236 million of share repurchases completed during the second quarter IQVIA Holdings Inc. , a leading global provider of advanced analytics, technology solutions, and contract research services to the life ...

  • TheStreet.com

    [video]IQVIA Holdings Expected to Earn $1.49 a Share

    IQVIA Holdings is expected to report net income of $298.4 million, or $1.49 a share, on sales of $2.7 billion before the market opens on Wednesday, based on a FactSet survey of 19 analysts. It reported net income of $69 million. The company offered guidance of $1.46 to $1.51 a share at the time of its last earnings report on May 1.

  • Fiserv (FISV) to Post Q2 Earnings: What's in the Offing?
    Zacks

    Fiserv (FISV) to Post Q2 Earnings: What's in the Offing?

    Fiserv's (FISV) second-quarter 2019 results to reflect revenue growth and better operating performance.

  • What's in Store for Republic Services (RSG) in Q2 Earnings?
    Zacks

    What's in Store for Republic Services (RSG) in Q2 Earnings?

    Republic Services' (RSG) second-quarter 2019 revenues are likely to benefit from internal growth and acquisitions.

  • Business Wire

    IQVIA Awarded Frost & Sullivan’s Life Sciences Product Leadership Award for Its Advanced Quality Management Technology Solution

    IQVIA™ today announced it has received the Frost & Sullivan’s 2018 Global Enterprise Quality Management Solutions for Life Sciences Product Leadership award. IQVIA Technologies’ SmartSolve®, a best-in-class, integrated enterprise quality management solution , was selected for its unique ability to address the needs of life sciences companies in quality management.

  • Is a Beat in Store for Waste Management (WM) in Q2 Earnings?
    Zacks

    Is a Beat in Store for Waste Management (WM) in Q2 Earnings?

    Waste Management (WM) second-quarter 2019 revenues are likely to benefit from strength across its collection and disposal business.

  • Equifax (EFX) to Report Q2 Earnings: What's in the Cards?
    Zacks

    Equifax (EFX) to Report Q2 Earnings: What's in the Cards?

    Equifax (EFX) second-quarter 2019 revenues are likely to reflect weakness in the USIS, International and Global Consumer Solutions segments.

  • What's in the Cards for Xerox (XRX) This Earnings Season?
    Zacks

    What's in the Cards for Xerox (XRX) This Earnings Season?

    Xerox's (XRX) second-quarter 2019 results are likely to reflect weakness in transactional revenues.